PHF21B: A Potential Drug Target and Biomarker (G112885)

Target Name: PHF21B

NCBI ID: G112885

PHF21B

PHF21B: A Potential Drug Target and Biomarker

PHF21B, also known as PHP, is a protein that is expressed in human tissues and has been shown to play a role in various physiological processes in the body. One of the most promising aspects of PHF21B is its potential as a drug target or biomarker. In this article, we will explore the biology of PHF21B, its potential drug targets, and its potential as a biomarker for various diseases.

PHF21B: Structure and Function

PHF21B is a 19 kDa protein that is expressed in various tissues, including muscle, heart, brain, and pancreas. It is a member of the PHF21 family, which includes several similar proteins that are involved in various signaling pathways in the body. PHF21B is characterized by a N-terminus that contains a leucine-rich repeat (LRR), a characteristic of the PHF21 family of proteins. The LRR is involved in the formation of a hydrogen bond with the carbonyl group of a lysine residue on the C-terminus of the protein.

PHF21B is involved in various physiological processes, including cell signaling, DNA replication, and metabolism. One of the most well-studied functions of PHF21B is its role in cell signaling. PHF21B has been shown to play a role in the regulation of T-cell development and function, as well as in the regulation of inflammation.

PHF21B has also been shown to be involved in DNA replication and metabolism. In fact, PHF21B has been shown to play a role in the regulation of DNA replication in various cell types, including normal human T-cells and cancer cells. This function of PHF21B is important because changes in DNA replication and metabolism have been linked to a variety of diseases, including cancer.

PHF21B as a Drug Target

PHF21B's involvement in cell signaling and metabolism make it an attractive target for drug development. One of the most promising approaches to targeting PHF21B is to use small molecules that can modulate its activity.

One class of small molecules that have been shown to interact with PHF21B is called IDOQs (inositol-dependent oxygenase inhibitors). IDOQs work by inhibiting the activity of an enzyme called IDO, which is involved in the production of inositol. Inositol is a signaling molecule that plays a role in various signaling pathways in the body, including cell signaling and metabolism.

IDOQs have been shown to be effective in modulating the activity of PHF21B. For example, one study shown that treatment with IDOQs significantly reduced the activity of PHF21B in human T-cells, indicating that PHF21B is involved in the regulation of IDO production. This suggests that IDOQs could be a useful tool for targeting PHF21B and modulating its activity.

Another class of small molecules that have been shown to interact with PHF21B are called DNA-binding proteins. DNA-binding proteins are proteins that are involved in the regulation of DNA replication and metabolism, and they can interact with PHF21B to modulate its activity.

One example of a DNA-binding protein that has been shown to interact with PHF21B is the protein named NEDD8. NEDD8 is a protein that is involved in the regulation of DNA replication and metabolism, and it has been shown to interact with PHF21B to modulate its activity.

PHF21B as a Biomarker

PHF21B has also been shown to be involved in the regulation of various physiological processes, including

Protein Name: PHD Finger Protein 21B

The "PHF21B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PHF21B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets